Travere Therapeutics secured FDA approval for Filspari (sparsentan) as the first fully approved treatment for focal segmental glomerulosclerosis (FSGS). The approval expands a label that already included accelerated and full approval for immunoglobulin A nephropathy (IgAN), establishing FSGS as a second commercial driver for the drug. The company’s submission relied on a regulatory package supporting proteinuria as a surrogate endpoint. The expanded indication covers children and adults aged 8 and older who do not have nephrotic syndrome, with the label exclusion highlighted by analysts as a nuance in patient eligibility. Following the regulatory milestone, Travere moved to position the therapy for both FSGS and its existing IgAN market opportunity, with early market reaction reflecting expectations for meaningful revenue upside if uptake matches projections.